

ARCHIVAL REPORT

A Randomized Clinical Trial of MK-0777 for the Treatment of Cognitive Impairments in People with Schizophrenia

Robert W. Buchanan, Richard S.E. Keefe, Jeffrey A. Lieberman, Deanna M. Barch, John G. Csernansky, Donald C. Goff, James M. Gold, Michael F. Green, L. Fredrik Jarskog, Daniel C. Javitt, David Kimhy, Michael S. Kraus, Joseph P. McEvoy, Raquelle I. Mesholam-Gately, Larry J. Seidman, M. Patricia Ball, Robert P. McMahon, Robert S. Kern, James Robinson, and Stephen R. Marder

Background: In a previous pilot study, MK-0777—a γ -aminobutyric acid (GABA)_A α 2/ α 3 partial agonist—was reported to improve delayed memory and cognitive measures of prefrontal cortical function in people with schizophrenia. The current study was designed to further examine the efficacy and safety of MK-0777 for the treatment of cognitive impairments in schizophrenia.

Methods: Sixty people with DSM-IV schizophrenia entered a 4-week, multi-center, double-blind, placebo-controlled, randomized clinical trial. Participants were randomized to: MK-0777 3 mg b.i.d. ($n = 18$); MK-0777 8 mg b.i.d. ($n = 21$); or placebo ($n = 21$). Participants were clinically stable. The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery, AX-Continuous Performance Test, and N-Back were used to assess cognition. The University of California San Diego (UCSD) Performance Based Skills Assessment-2 and the Schizophrenia Cognition Rating Scale assessed functional capacity and served as functional outcome coprimary measures.

Results: There were no significant group differences on the primary outcome measure, the MATRICS Consensus Cognitive Battery composite score. Secondary analyses suggested that participants randomized to placebo performed significantly better on visual memory and reasoning/problem-solving tests than participants assigned to either MK-0777 dose. There were no significant group differences on the AX-Continuous Performance Test or N-Back d prime scores or UCSD Performance-Based Skills Assessment-2 and Schizophrenia Cognition Rating Scale total scores. In general, MK-0777 was well-tolerated with minimal side effects.

Conclusions: The study results suggest that MK-0777 has little benefit for cognitive impairments in people with schizophrenia. The GABA_A receptor remains a promising target, but a more potent partial agonist with greater intrinsic activity at the GABA_A α 2 site might be needed for cognitive enhancement in schizophrenia.

Key Words: Clinical trial, cognition, functional capacity, γ -aminobutyric acid, schizophrenia, symptoms

People with schizophrenia have a broad range of neurocognitive impairments, including abnormalities in attention, executive function, visual and verbal learning and memory, working memory, processing speed, and social cognition

From the Maryland Psychiatric Research Center (RWB, JMG, MPB, RPM), Department of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland; Department of Psychiatry and Behavioral Sciences (RSEK, MSK, JPM), Duke University Medical Center, Durham, North Carolina; Department of Psychiatry (JAL, LFI, DK), New York State Psychiatric Institute and College of Physicians and Surgeons, Columbia University; Department of Psychiatry (DCJ, JR), Nathan Kline Institute for Psychiatric Research, New York University School of Medicine, New York, New York; Department of Psychiatry (DMB), Washington University in St. Louis School of Medicine, St. Louis, Missouri; Department of Psychiatry (JGC), Northwestern Feinberg School of Medicine, Chicago, Illinois; Department of Psychiatry (DCG, LJS), Massachusetts General Hospital, Harvard Medical School; Department of Psychiatry (RIM-G, LJS), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; and UCLA Semel Institute for Neuroscience and Human Behavior (MFG, RSK, SRM) and the VA VISN 22 Mental Illness Research, Education, and Clinical Center (MFG, RSK, SRM), Los Angeles, California.

Address correspondence to Robert W. Buchanan, M.D., University of Maryland School of Medicine, Grounds of Spring Grove Hospital, Department of Psychiatry, Maple and Locust Streets, PO Box 21247, Baltimore, MD 21228; E-mail: rwbuchanan@mprc.umaryland.edu.

Received May 12, 2010; revised Aug 20, 2010; accepted Sep 16, 2010.

0006-3223/\$36.00
doi:10.1016/j.biopsych.2010.09.052

(1). These impairments are major determinants of functional outcome in schizophrenia (2,3). First- and second-generation antipsychotics have limited benefits for these impairments (4). The use of add-on pharmacological agents might offer a viable approach for the treatment of these impairments, because they can be used to modulate specific neurotransmitter systems hypothesized to be involved in the pharmacology of cognitive functions.

γ -aminobutyric acid (GABA) is the major central nervous system inhibitory neurotransmitter. GABAergic mechanisms are important for regulation of prefrontal cortical function, through their modulation of glutamatergic pyramidal cells (5). In particular, the GABAergic chandelier cell type interneuron inhibits pyramidal neuron output through activation of GABA receptors containing the α 2 subunit located on the axon initial segment, a mechanism thought to support the development and maintenance of recurrent activity necessary for intact prefrontal function (5).

Postmortem studies have found decreased levels of glutamic acid decarboxylase (GAD)₆₇ messenger RNA expression in the prefrontal cortex (6–9). The GAD₆₇ reduction seems to be restricted to those cells that contain the calcium-binding protein parvalbumin, which includes chandelier cell interneurons (7,10). In people with schizophrenia with decreased GAD₆₇, there is also a decrease in GABA reuptake transporter messenger RNA levels (11); the density of chandelier cell connections with the pyramidal cell axon initial segment (12,13); and immunoreactivity of the GABA plasma membrane transporter-1 in chandelier cell axon terminals (12). Finally, there seems to be a marked increase in GABA_A α 2 subunit density on the axon initial segment (14).

These postmortem results are consistent with a marked decrease in GABAergic inhibition of dorsolateral prefrontal cortex pyramidal cell glutamatergic transmission, which could have important implications for our understanding of cognitive impairments in schizophrenia (5). Specifically, intact GABAergic function has been shown to be required for normal working memory (15–18). People with schizophrenia have been shown to have verbal and visual working memory impairments (1,19–24). Working memory might also be critical for a number of other cognitive processes, so that improvement of working memory function could lead to improvement in other cognitive domains. Agents that increase GABA inhibition of cortical pyramidal cells would be hypothesized to improve working memory and possibly other cognitive impairments.

MK-0777 is a GABA_A α 2/ α 3 partial agonist, with approximately 10%–20% of the potency of a full GABA_A α 2 agonist. MK-0777 is functionally selective for the α 2 and α 3 subunits, with virtually no activity for the α 1 and α 5 subunits (25,26). Therefore, it is hypothesized to cause less sedation than benzodiazepines (27). In animal studies, MK-0777 was observed to cause less sedation, interact less with alcohol, and exhibit less abuse potential and physical dependence than benzodiazepines (25,26). In a previous pilot study, MK-0777 improved delayed memory performance and decreased reaction time on selected measures of prefrontal cortical function (28). The purpose of the current study was to conduct a larger scale trial to examine the efficacy and safety of two doses of MK-0777, 3 mg b.i.d. and 8 mg b.i.d., in the treatment of cognitive impairments in people with schizophrenia.

Methods and Materials

The National Institute of Mental Health Treatment Units for Research on Neurocognition in Schizophrenia Network implemented the 4-week, placebo-controlled, parallel group, double-blind study. Inpatients or outpatients 18–60 years of age, who met DSM-IV-TR criteria for schizophrenia, were selected for study entry. Participants were diagnosed on the basis of information from the Structured Clinical Interview for DSM-IV (29), direct assessment, family informants, and past medical records. Participants were required to be clinically stable and in the nonacute phase of their illness and to meet the following inclusion criteria (30): 1) treatment with one second-generation antipsychotic medication other than clozapine for the previous 2 months, with no dose change in the month before study entry; 2) Brief Psychiatric Rating Scale (BPRS) (31) hallucinatory behavior and unusual thought content item scores \leq 4; 3) BPRS conceptual disorganization item \leq 4; 4) Simpson-Angus Scale (SAS) (32) total score \leq 6; and 5) Calgary Depression Scale (CDS) (33) total score \leq 10 (30,34). To facilitate recruitment, the aforementioned criteria were amended halfway through the study to allow treatment with no more than two second-generation antipsychotic medications other than clozapine, and the cut-off score for BPRS hallucinatory behavior and unusual thought content items was changed to \leq 5.

Participants were required to validly complete the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) (35,36) (i.e., the neuropsychological tester and the site neuropsychologist judged their performance to reliably reflect their ability on those aspects of cognition that the test was intended to measure). To minimize potential ceiling effects, participants were required to score at least 1 SD below maximum on one or more of the following tests: Letter-Number Span; Hopkins Verbal Learning Test; and Identical Pairs Continuous Performance Test (CPT). Finally, participants were required to have a Wechsler Test of Adult Reading (37) raw score \geq 6.

Participants were excluded if they had a DSM-IV diagnosis of alcohol or substance abuse (other than nicotine) within the last month, alcohol or substance dependence (other than nicotine) within the last 6 months, or mental retardation; had a history of significant head injury/trauma or clinically significant medical or neurological disease; were treated with drugs known to act at the GABA_A receptor or to inhibit CYP3A4; had a history of severe benzodiazepine withdrawal; or participated in a clinical trial of investigational medication within 60 days. Women of childbearing age were included if using adequate birth control.

The institutional review boards approved the study protocol and informed consent procedures. Written informed consent was obtained from all participants after study procedures had been fully explained and before study participation. Participant ability to provide valid informed consent was documented with study specific procedures.

Assessments

The MCCB was used to assess neuropsychological test performance. The MCCB comprises 10 tests, which assess seven cognitive domains (35). The MCCB composite score is a standardized mean of the seven domain scores. The *T* scores are standardized to normative data and have an estimated mean of 50 and SD of 10 in the general healthy population (36).

In addition, because of their previous use to evaluate cognitive effects with this compound (28), the AX-CPT (38) and the N-Back (39) were used to assess prefrontal cortical cognitive function. The AX-CPT is a modification of the traditional CPT, in which AX trial frequency is increased to 70%. The increased AX trial frequency requires greater use of context to overcome the induced propensity to respond to the “X” probe on trials that do not contain the “A” cue (40). The N-Back is a sequential letter working memory task, which varies working memory load by requiring the participant to identify whether the test stimulus is identical to the immediately preceding letter (0-back) or the letter presented 1 trial back (1-back) or two trials back (2-back) (39).

A modified version of the University of California San Diego (UCSD) Performance-Based Skills Assessment (UPSA) (40), the UPSA-2, was used to assess functional capacity. The UPSA-2 contains a sixth component: Medication Management, and the content complexity and number of items required to be remembered were increased for the Comprehension/Planning, Financial Skills, and Transportation components to reduce potential for ceiling effects. The Schizophrenia Cognition Rating Scale (SCoRS) (41) is an interview-based measure used to assess cognition. The MCCB, UPSA-2, SCoRS, AX-CPT, and N-back were obtained at Evaluation Week 1 and Treatment Phase Week 4.

The BPRS positive symptom item total score was used to assess positive symptom change. The BPRS positive symptom items are conceptual disorganization, hallucinatory behavior, unusual thought content, and suspiciousness. The modified Scale for the Assessment of Negative Symptoms (SANS) (42) total score was used to assess negative symptom change. The CDS was used to assess depressive symptom change. The Clinical Global Impression severity of illness item (CGI-S) was used to assess global changes. The BPRS, SANS, CDS, and CGI-S were obtained at Screening, Evaluation Phase Week 2, and biweekly during the Treatment Phase.

The MCCB and UPSA raters were trained on the administration and scoring of these instruments with video and group training sessions and were individually certified by an expert on these assessments. The SCoRS raters were trained in a group education format, in which they viewed and scored a series of videotapes. Symptom raters were required to be reliable on the BPRS and SANS

(intraclass correlation $\geq .80$). Quarterly reliability meetings were conducted throughout the study to ensure that the raters maintained the intersite intraclass correlation criterion of $\geq .80$. All raters were blind to treatment assignment.

Safety Assessments

The SAS (32) and Abnormal Involuntary Movement Scale (AIMS) (43) were used to assess abnormal motor movements. The SAS and AIMS were administered at Screening, Evaluation Phase Week 2, and biweekly during the Treatment Phase.

A standard chemistry panel, complete blood count, urinalysis and urine toxicology screen, and electrocardiogram were obtained at Screening and at the end of the Treatment Phase. The Side Effect Checklist (SEC) was used to assess side effects and monitor vital signs. The SEC comprises 22 common side effects, which are rated from 1 (none) to 4 (severe). The SEC and vital sign ratings were conducted at Evaluation Phase Weeks 1 and 2 and weekly during the Treatment Phase.

Study Design

Participants who met inclusion criteria entered a 2-week Evaluation Phase during which they underwent baseline cognitive, symptom, and safety assessments. Participants who continued to meet inclusion criteria entered the 4-week, double-blind Treatment Phase and were randomized to MK-0777 3 mg b.i.d.; MK-0777 8 mg b.i.d.; or placebo b.i.d. Participants randomized to MK-0777 8 mg b.i.d. were started on 3 mg b.i.d., and their dose was titrated over the first week to the target dose. Participants randomized to MK-0777 3 mg b.i.d. were started on this dose. The MK-0777 $t_{1/2}$ is approximately 7 hours and the T_{max} is 6–7 hours; therefore we used a twice daily dosing schedule.

If side effects interfered with the tolerability of the study medication, the participant was instructed to skip a dose and then resume treatment with the prescribed dose. If still unable to tolerate the study medication, then the dose could be lowered to alleviate side effects. The side effects most likely to affect MK-0777 tolerability were dizziness, incoordination, and sedation. At the end of the Treatment Phase, all participants were tapered off their study medication to minimize potential withdrawal effects.

The study biostatistician established computer-generated randomization sequences for each site. Randomization was performed with the permuted block method, randomly drawing from 3 or 6 size blocks, to limit imbalance in numbers between groups. Until the trial was concluded, the randomization sequence was only available to the biostatistician and to an unblinded pharmacist at each site, whose only role was to dispense medication. In response to a randomization request, the biostatistician sent a code number to the unblinded pharmacist, which identified the next treatment selection to be dispensed from the treatment sequence. Randomization was stratified by site.

Medication compliance was assessed by weekly pill count. All participants who received 75% or more of their assigned study medication were considered compliant.

Statistical Analyses

The sample size was determined with the analysis of covariance (ANCOVA) power formula, $n = 2(z_{\alpha} + z_{\beta})^2 s^2 (1 - R^2)/d^2$, with $z_{\alpha} = 2.24$, $z_{\beta} = .842$ (corresponding to power = .80), R = the correlation between baseline and end of study measures of the primary outcome (estimated to equal .6 for the MCCB composite score), d the difference between groups, and s the SD of the primary outcome. We planned to enroll 30 participants/group, which would have enabled us to detect an effect size = .73 with power = .80. The

actual recruitment was only approximately 20 participants/group, but the observed R approximately = .9, suggesting power to detect an effect size of .49.

An ANCOVA, adjusting for baseline scores, was used to compare treatment groups on cognitive and functional measures. The predefined primary cognition outcome measure was the MCCB composite T score, tested at overall two-sided $\alpha = .05$. The predefined primary functional outcome measure was the UPSA summary score. Exploratory analysis of variation in treatment effects among the different MCCB measures was performed with the mixed model for repeated measures ANCOVA: Week 4 T -score = baseline T score + measure + treatment + treatment \times measure, where measure was a categorical variable indicating the different MCCB tests, and the treatment \times measure effect tested whether the treatment effect differed significantly among the various tests.

The AX-CPT and N-back accuracy results were summarized with the d -prime statistic (44). For the AX-CPT, only BX trials were used to calculate the false alarm rate. For the N-back, trials with novel and repeated distractors were pooled in calculating the false alarm rate. The N-back response times (RTs) were analyzed with the ANCOVA model $\log(\text{RT}) = \text{baseline } \log(\text{RT}) + \text{response type} + \text{treatment} + \text{treatment} \times \text{response type}$, where response type distinguishes target, repeat nontarget, and novel nontarget trials.

Symptom data were analyzed with a mixed model for unbalanced repeated measures ANCOVA, with data from all participants who completed at least one symptom assessment to fit the model: follow-up score = baseline score + treatment + week + treatment \times week, where the treatment effect tests the average difference across weeks between treatment groups, and the treatment \times week interaction assesses whether this difference varies between Weeks 2 and 4. Mixed models were fitted with SAS PROC MIXED (SAS, Cary, North Carolina), with the Kenward-Rogers method to estimate degrees of freedom. The treatment \times week interaction was nonsignificant for all variables assessed, and only average difference tests and estimates are reported.

Group differences on SAS and AIMS total scores were examined by calculating the τ - b rank correlation between score and week for each participant and comparing the distribution of these trend scores with the Conover-Salsburg rank test (45,46). Fisher exact test was used to compare treatments on the number of participants who, at any point during follow-up, had new or worsened (compared with baseline) side effect severity. The effects of treatment on laboratory assays were tested with ANCOVA, whereas the effects of treatment on vital signs were tested with mixed model ANCOVA.

Results

The study was conducted between July 2007 and June 2009. Sixty-four participants were randomized: 19 were randomized to MK-0777 3 mg b.i.d.; 22 were randomized to MK-0777 8 mg b.i.d.; and 23 were randomized to placebo (see Figure S1 in Supplement 1 for participant flow details). Fifty-three participants completed the study: MK-0777 3 mg b.i.d.: $n = 18$; MK-0777 8 mg b.i.d.: $n = 18$; placebo: $n = 17$. Three participants dropped out before receiving study drug (one randomized to each group), and one participant dropped out before any postrandomization ratings (randomized to placebo). These participants were not included in either efficacy or safety analyses. The demographic and baseline clinical characteristics of participants included in either analysis are presented in Table 1.

MCCB

There were no overall significant group differences on MCCB composite score change [$F(2,49) = 1.61$; $p = .21$] (Table 2). In

Table 1. Demographic Data and Baseline Clinical Characteristics

	Placebo (<i>n</i> = 21) mean (\pm SD)	MK-0777, 3 mg b.i.d. (<i>n</i> = 18) mean (\pm SD)	MK-0777, 8 mg b.i.d. (<i>n</i> = 21) mean (\pm SD)
Age, yrs	40.0 (10.9)	43.3 (9.3)	44.9 (8.7)
Education, yrs	12.2 (2.5)	13.3 (3.0)	14.2 (2.4)
Gender (male)	77.3%	61.1%	61.9%
Race (white)	45.4%	50.0%	42.9%
WTAR Score	29.2 (10.3)	27.1 (12.0)	29.7 (14.0)
MCCB Composite Score	30.1 (13.1)	31.0 (12.6)	27.8 (12.2)
BPRS Total Score	26.8 (6.4)	28.9 (5.2)	29.8 (6.2)
BPRS Positive Symptom Item Score	7.0 (3.5)	7.6 (2.8)	6.8 (2.1)
SANS Total Score	18.6 (11.5)	17.8 (10.5)	20.6 (14.7)
CDS Total Score	1.6 (1.5)	2.1 (2.4)	2.0 (2.1)
SAS Total Score	1.1 (1.5)	.8 (1.2)	1.4 (1.6)

WTAR, Wechsler Test of Adult Reading; MCCB, MATRICS Consensus Cognitive Battery; BPRS, Brief Psychiatric Rating Scale; SANS, Scale for the Assessment of Negative Symptoms; CDS, Calgary Depression Scale; SAS, Simpson-Angus Scale.

exploratory post hoc pair-wise analyses of individual test scores, there were nominally significant differences (unadjusted $p < .05$) between the MK-0777 8 mg b.i.d. and placebo groups on the Brief Visual Memory Test-Revised [$t(46.9) = 2.45; p = .02$] and the Neuropsychological Assessment Battery mazes test [$t(46.8) = 2.71; p = .009$], with participants randomized to placebo exhibiting greater improvement on both of the measures.

The test-retest reliability for the MCCB composite score was .95 (Pearson correlation between baseline and end of study assess-

ments), with the correlation for each of the individual domains ranging from .72 to .90 (Table S1 in Supplement 1). In the placebo group, there were small but significant time effects for the MCCB composite score [$t(16) = 5.25; p < .001$] and the verbal learning [$t(16) = 2.12; p = .05$] and reasoning/problem-solving [$t(16) = 4.28; p < .001$] domains (Table S1 in Supplement 1).

Ancillary Cognitive Measures

There were no overall significant group differences for change in AX-CPT performance [$F(2,43) = .25; p = .78$] (Table 3). The overall ANCOVA tests for group differences on the 0-back [$F(2,46) = .01; p = .99$], 1-back [$F(2,46) = .35; p = .71$], and 2-back [$F(2,46) = .97; p = .39$] d-prime scores were all statistically nonsignificant. The post hoc pair-wise group comparisons for the AX-CPT and N-back d prime measures were all nonsignificant. The 2-back RTs for the different response types—target hit, novel correct rejection, and repeated correct rejection—are presented in Table 4. The overall ANCOVA for treatment differences in RTs for the three different response types was not significant [$F(2,47) = 1.23; p = .30$]; nor was the response type \times treatment group interaction [$F(4,54.2) = .95; p = .44$].

The test-retest reliability for AX-CPT d-prime was .67 and ranged from .68 (0-back) to .84 (1-back) for the N-back measures (Table S2 in Supplement 1). In the placebo group, there was a significant time effect for the 2-back d-prime measure [$t(16) = 2.18; p = .04$] (Table S2 in Supplement 1).

Functional Assessments

The overall ANCOVA for treatment effects on the UPSA-2 summary score was nonsignificant [placebo: Week 0: 95.0 ± 16.26 , and Week 4: 96.5 ± 15.5 ; MK-077 3 mg b.i.d.: Week 0: 85.0 ± 18.8 , and Week 4: 86.3 ± 18.7 ; MK-077 8 mg b.i.d.: Week 0: 91.7 ± 13.4 , and Week 4: 90.4 ± 12.8 ; $F(2,50) = .77; p = .47$]. There was a significant

Table 2. MCCB Composite and Individual Test T Scores

Measure	Week	Placebo (<i>n</i> = 17)	MK-0777 3 mg b.i.d. (<i>n</i> = 15)	MK-0777 8 mg b.i.d. (<i>n</i> = 18)	ANCOVA																																																																																																																						
					<i>F</i>	<i>df</i>	<i>p</i>																																																																																																																				
MCCB Composite	0	30.1 (13.1)	31.0 (12.6)	27.8 (12.2)	1.61	2,49.0	.210																																																																																																																				
	4	32.5 (14.0)	31.3 (13.9)	27.9 (12.7)				CPT-IP	0	38.8 (9.2)	41.3 (13.7)	36.9 (9.8)	.72	2,46.8	.492	4	38.1 (12.0)	42.9 (13.7)	36.8 (10.6)	BACS Symbol Coding	0	33.9 (10.8)	36.4 (10.1)	32.9 (11.8)	.06	2,46.8	.492	4	33.5 (12.5)	35.3 (11.2)	32.0 (11.7)	Category Fluency	0	40.2 (8.5)	42.7 (8.0)	39.9 (10.4)	.39	2,47.0	.679	4	41.7 (9.6)	42.7 (8.2)	39.3 (12.2)	Trails A	0	38.8 (15.3)	40.5 (12.2)	35.2 (11.5)	.09	2,46.8	.917	4	40.2 (15.2)	41.5 (11.4)	38.3 (14.4)	BVM-T-R	0	36.4 (12.2)	36.5 (11.1)	34.5 (14.6)	3.18	2,46.9	.051	4	39.7 (11.9)	35.9 (10.5)	33.1 (11.9)	HVL-T-R	0	39.7 (9.8)	38.0 (9.6)	37.8 (7.7)	1.44	2,47.0	.248	4	43.2 (8.8)	39.3 (12.2)	37.7 (8.7)	MSCEIT	0	40.2 (10.8)	36.9 (18.9)	35.3 (11.1)	.40	2,47.1	.671	4	39.0 (11.2)	37.8 (16.4)	37.7 (14.1)	NAB Mazes	0	40.2 (9.4)	40.1 (6.3)	37.7 (8.5)	3.77	2,46.7	.030	4	44.1 (10.6)	41.3 (6.6)	37.9 (7.6)	WMS-III Spatial Span	0	38.7 (10.1)	42.7 (7.2)	39.8 (13.2)	.20	2,46.4	.816	4	40.8 (13.2)	42.9 (8.6)	40.2 (13.6)	LNS	0	37.1 (12.1)	35.9 (12.7)	38.7 (12.6)	1.88	2,45.8	.163
CPT-IP	0	38.8 (9.2)	41.3 (13.7)	36.9 (9.8)	.72	2,46.8	.492																																																																																																																				
	4	38.1 (12.0)	42.9 (13.7)	36.8 (10.6)				BACS Symbol Coding	0	33.9 (10.8)	36.4 (10.1)	32.9 (11.8)	.06	2,46.8	.492	4	33.5 (12.5)	35.3 (11.2)	32.0 (11.7)	Category Fluency	0	40.2 (8.5)	42.7 (8.0)	39.9 (10.4)	.39	2,47.0	.679	4	41.7 (9.6)	42.7 (8.2)	39.3 (12.2)	Trails A	0	38.8 (15.3)	40.5 (12.2)	35.2 (11.5)	.09	2,46.8	.917	4	40.2 (15.2)	41.5 (11.4)	38.3 (14.4)	BVM-T-R	0	36.4 (12.2)	36.5 (11.1)	34.5 (14.6)	3.18	2,46.9	.051	4	39.7 (11.9)	35.9 (10.5)	33.1 (11.9)	HVL-T-R	0	39.7 (9.8)	38.0 (9.6)	37.8 (7.7)	1.44	2,47.0	.248	4	43.2 (8.8)	39.3 (12.2)	37.7 (8.7)	MSCEIT	0	40.2 (10.8)	36.9 (18.9)	35.3 (11.1)	.40	2,47.1	.671	4	39.0 (11.2)	37.8 (16.4)	37.7 (14.1)	NAB Mazes	0	40.2 (9.4)	40.1 (6.3)	37.7 (8.5)	3.77	2,46.7	.030	4	44.1 (10.6)	41.3 (6.6)	37.9 (7.6)	WMS-III Spatial Span	0	38.7 (10.1)	42.7 (7.2)	39.8 (13.2)	.20	2,46.4	.816	4	40.8 (13.2)	42.9 (8.6)	40.2 (13.6)	LNS	0	37.1 (12.1)	35.9 (12.7)	38.7 (12.6)	1.88	2,45.8	.163	4	36.7 (11.9)	40.0 (14.2)	38.6 (13.4)								
BACS Symbol Coding	0	33.9 (10.8)	36.4 (10.1)	32.9 (11.8)	.06	2,46.8	.492																																																																																																																				
	4	33.5 (12.5)	35.3 (11.2)	32.0 (11.7)				Category Fluency	0	40.2 (8.5)	42.7 (8.0)	39.9 (10.4)	.39	2,47.0	.679	4	41.7 (9.6)	42.7 (8.2)	39.3 (12.2)	Trails A	0	38.8 (15.3)	40.5 (12.2)	35.2 (11.5)	.09	2,46.8	.917	4	40.2 (15.2)	41.5 (11.4)	38.3 (14.4)	BVM-T-R	0	36.4 (12.2)	36.5 (11.1)	34.5 (14.6)	3.18	2,46.9	.051	4	39.7 (11.9)	35.9 (10.5)	33.1 (11.9)	HVL-T-R	0	39.7 (9.8)	38.0 (9.6)	37.8 (7.7)	1.44	2,47.0	.248	4	43.2 (8.8)	39.3 (12.2)	37.7 (8.7)	MSCEIT	0	40.2 (10.8)	36.9 (18.9)	35.3 (11.1)	.40	2,47.1	.671	4	39.0 (11.2)	37.8 (16.4)	37.7 (14.1)	NAB Mazes	0	40.2 (9.4)	40.1 (6.3)	37.7 (8.5)	3.77	2,46.7	.030	4	44.1 (10.6)	41.3 (6.6)	37.9 (7.6)	WMS-III Spatial Span	0	38.7 (10.1)	42.7 (7.2)	39.8 (13.2)	.20	2,46.4	.816	4	40.8 (13.2)	42.9 (8.6)	40.2 (13.6)	LNS	0	37.1 (12.1)	35.9 (12.7)	38.7 (12.6)	1.88	2,45.8	.163	4	36.7 (11.9)	40.0 (14.2)	38.6 (13.4)																				
Category Fluency	0	40.2 (8.5)	42.7 (8.0)	39.9 (10.4)	.39	2,47.0	.679																																																																																																																				
	4	41.7 (9.6)	42.7 (8.2)	39.3 (12.2)				Trails A	0	38.8 (15.3)	40.5 (12.2)	35.2 (11.5)	.09	2,46.8	.917	4	40.2 (15.2)	41.5 (11.4)	38.3 (14.4)	BVM-T-R	0	36.4 (12.2)	36.5 (11.1)	34.5 (14.6)	3.18	2,46.9	.051	4	39.7 (11.9)	35.9 (10.5)	33.1 (11.9)	HVL-T-R	0	39.7 (9.8)	38.0 (9.6)	37.8 (7.7)	1.44	2,47.0	.248	4	43.2 (8.8)	39.3 (12.2)	37.7 (8.7)	MSCEIT	0	40.2 (10.8)	36.9 (18.9)	35.3 (11.1)	.40	2,47.1	.671	4	39.0 (11.2)	37.8 (16.4)	37.7 (14.1)	NAB Mazes	0	40.2 (9.4)	40.1 (6.3)	37.7 (8.5)	3.77	2,46.7	.030	4	44.1 (10.6)	41.3 (6.6)	37.9 (7.6)	WMS-III Spatial Span	0	38.7 (10.1)	42.7 (7.2)	39.8 (13.2)	.20	2,46.4	.816	4	40.8 (13.2)	42.9 (8.6)	40.2 (13.6)	LNS	0	37.1 (12.1)	35.9 (12.7)	38.7 (12.6)	1.88	2,45.8	.163	4	36.7 (11.9)	40.0 (14.2)	38.6 (13.4)																																
Trails A	0	38.8 (15.3)	40.5 (12.2)	35.2 (11.5)	.09	2,46.8	.917																																																																																																																				
	4	40.2 (15.2)	41.5 (11.4)	38.3 (14.4)				BVM-T-R	0	36.4 (12.2)	36.5 (11.1)	34.5 (14.6)	3.18	2,46.9	.051	4	39.7 (11.9)	35.9 (10.5)	33.1 (11.9)	HVL-T-R	0	39.7 (9.8)	38.0 (9.6)	37.8 (7.7)	1.44	2,47.0	.248	4	43.2 (8.8)	39.3 (12.2)	37.7 (8.7)	MSCEIT	0	40.2 (10.8)	36.9 (18.9)	35.3 (11.1)	.40	2,47.1	.671	4	39.0 (11.2)	37.8 (16.4)	37.7 (14.1)	NAB Mazes	0	40.2 (9.4)	40.1 (6.3)	37.7 (8.5)	3.77	2,46.7	.030	4	44.1 (10.6)	41.3 (6.6)	37.9 (7.6)	WMS-III Spatial Span	0	38.7 (10.1)	42.7 (7.2)	39.8 (13.2)	.20	2,46.4	.816	4	40.8 (13.2)	42.9 (8.6)	40.2 (13.6)	LNS	0	37.1 (12.1)	35.9 (12.7)	38.7 (12.6)	1.88	2,45.8	.163	4	36.7 (11.9)	40.0 (14.2)	38.6 (13.4)																																												
BVM-T-R	0	36.4 (12.2)	36.5 (11.1)	34.5 (14.6)	3.18	2,46.9	.051																																																																																																																				
	4	39.7 (11.9)	35.9 (10.5)	33.1 (11.9)				HVL-T-R	0	39.7 (9.8)	38.0 (9.6)	37.8 (7.7)	1.44	2,47.0	.248	4	43.2 (8.8)	39.3 (12.2)	37.7 (8.7)	MSCEIT	0	40.2 (10.8)	36.9 (18.9)	35.3 (11.1)	.40	2,47.1	.671	4	39.0 (11.2)	37.8 (16.4)	37.7 (14.1)	NAB Mazes	0	40.2 (9.4)	40.1 (6.3)	37.7 (8.5)	3.77	2,46.7	.030	4	44.1 (10.6)	41.3 (6.6)	37.9 (7.6)	WMS-III Spatial Span	0	38.7 (10.1)	42.7 (7.2)	39.8 (13.2)	.20	2,46.4	.816	4	40.8 (13.2)	42.9 (8.6)	40.2 (13.6)	LNS	0	37.1 (12.1)	35.9 (12.7)	38.7 (12.6)	1.88	2,45.8	.163	4	36.7 (11.9)	40.0 (14.2)	38.6 (13.4)																																																								
HVL-T-R	0	39.7 (9.8)	38.0 (9.6)	37.8 (7.7)	1.44	2,47.0	.248																																																																																																																				
	4	43.2 (8.8)	39.3 (12.2)	37.7 (8.7)				MSCEIT	0	40.2 (10.8)	36.9 (18.9)	35.3 (11.1)	.40	2,47.1	.671	4	39.0 (11.2)	37.8 (16.4)	37.7 (14.1)	NAB Mazes	0	40.2 (9.4)	40.1 (6.3)	37.7 (8.5)	3.77	2,46.7	.030	4	44.1 (10.6)	41.3 (6.6)	37.9 (7.6)	WMS-III Spatial Span	0	38.7 (10.1)	42.7 (7.2)	39.8 (13.2)	.20	2,46.4	.816	4	40.8 (13.2)	42.9 (8.6)	40.2 (13.6)	LNS	0	37.1 (12.1)	35.9 (12.7)	38.7 (12.6)	1.88	2,45.8	.163	4	36.7 (11.9)	40.0 (14.2)	38.6 (13.4)																																																																				
MSCEIT	0	40.2 (10.8)	36.9 (18.9)	35.3 (11.1)	.40	2,47.1	.671																																																																																																																				
	4	39.0 (11.2)	37.8 (16.4)	37.7 (14.1)				NAB Mazes	0	40.2 (9.4)	40.1 (6.3)	37.7 (8.5)	3.77	2,46.7	.030	4	44.1 (10.6)	41.3 (6.6)	37.9 (7.6)	WMS-III Spatial Span	0	38.7 (10.1)	42.7 (7.2)	39.8 (13.2)	.20	2,46.4	.816	4	40.8 (13.2)	42.9 (8.6)	40.2 (13.6)	LNS	0	37.1 (12.1)	35.9 (12.7)	38.7 (12.6)	1.88	2,45.8	.163	4	36.7 (11.9)	40.0 (14.2)	38.6 (13.4)																																																																																
NAB Mazes	0	40.2 (9.4)	40.1 (6.3)	37.7 (8.5)	3.77	2,46.7	.030																																																																																																																				
	4	44.1 (10.6)	41.3 (6.6)	37.9 (7.6)				WMS-III Spatial Span	0	38.7 (10.1)	42.7 (7.2)	39.8 (13.2)	.20	2,46.4	.816	4	40.8 (13.2)	42.9 (8.6)	40.2 (13.6)	LNS	0	37.1 (12.1)	35.9 (12.7)	38.7 (12.6)	1.88	2,45.8	.163	4	36.7 (11.9)	40.0 (14.2)	38.6 (13.4)																																																																																												
WMS-III Spatial Span	0	38.7 (10.1)	42.7 (7.2)	39.8 (13.2)	.20	2,46.4	.816																																																																																																																				
	4	40.8 (13.2)	42.9 (8.6)	40.2 (13.6)				LNS	0	37.1 (12.1)	35.9 (12.7)	38.7 (12.6)	1.88	2,45.8	.163	4	36.7 (11.9)	40.0 (14.2)	38.6 (13.4)																																																																																																								
LNS	0	37.1 (12.1)	35.9 (12.7)	38.7 (12.6)	1.88	2,45.8	.163																																																																																																																				
	4	36.7 (11.9)	40.0 (14.2)	38.6 (13.4)																																																																																																																							

Values are mean (\pm SD); there was no significant variation in the magnitude of treatment differences among the cognitive measures [$F(18) = .73, p = .76$].

MCCB, MATRICS Consensus Cognitive Battery; ANCOVA, analysis of covariance; CPT-IP, Identical Pairs Continuous Performance Test; BACS, Brief Assessment of Cognition in Schizophrenia; BVM-T-R, Brief Visuospatial Memory Test-Revised; HVL-T-R, Hopkins Verbal Learning Test-Revised; MSCEIT, Mayer-Salovey-Caruso Emotional Intelligence Test; NAB, Neuropsychological Assessment Battery; WMS, Wechsler Memory Scale; LNS, Letter-Number Span.

Table 3. N-Back and AX-CPT d-Prime Scores

Measure	Placebo		MK-0777, 3 mg b.i.d.		MK-0777, 8 mg b.i.d.		ANCOVA		
	Week 0	Week 4	Week 0	Week 4	Week 0	Week 4	<i>F</i>	<i>df</i>	<i>p</i>
N-Back	(<i>n</i> = 17)	(<i>n</i> = 17)	(<i>n</i> = 16)	(<i>n</i> = 16)	(<i>n</i> = 18)	(<i>n</i> = 17)			
0-Back	3.7 (0.5)	3.7 (0.6)	3.7 (0.6)	3.7 (0.6)	3.4 (0.5)	3.6 (0.6)	.01	2,46	0.98
1-Back	2.7 (0.8)	2.8 (0.8)	3.0 (0.6)	3.0 (0.7)	2.7 (0.8)	2.6 (0.6)	.35	2,46	0.71
2-Back	1.4 (0.8)	1.6 (0.6)	1.4 (0.6)	1.4 (0.6)	1.5 (0.8)	1.4 (0.6)	.97	2,46	0.39
AX-CPT	(<i>n</i> = 16)	(<i>n</i> = 16)	(<i>n</i> = 16)	(<i>n</i> = 16)	(<i>n</i> = 15)	(<i>n</i> = 15)			
d-Prime	2.4 (1.1)	2.2 (1.4)	2.5 (1.1)	2.5 (1.2)	2.0 (1.2)	2.0 (1.1)	.25	2,43	0.78

Values are mean (\pm SD).

CPT, Continuous Performance Test; ANCOVA, analysis of covariance.

group difference on the UPSA Comprehension/Planning component (Table S3 in Supplement 1). In the post hoc, pair-wise analyses, participants randomized to placebo improved significantly more than those randomized to MK-0777 8 mg b.i.d. [$t(50) = 2.68$; $p = .01$], with a trend for the placebo group to also perform better than the MK-077 3 mg b.i.d. group [$t(50) = 1.96$; $p = .06$] on this measure. There were no other significant treatment group differences on the UPSA component measures.

The overall ANCOVA for treatment effects on the SCoRS Interviewer Global rating was nonsignificant [placebo: Week 0: 3.8 ± 2.3 , and Week 4: 3.6 ± 1.8 ; MK-077 3 mg b.i.d.: Week 0: 4.8 ± 2.3 , and Week 4: 4.6 ± 2.1 ; MK-077 8 mg b.i.d.: Week 0: 4.1 ± 2.3 , and Week 4: 4.0 ± 2.4 ; $F(2,47) = .17$; $p = .84$]. There were also no significant treatment differences on the participant, informant, and interviewer change rating scores (all F values $< .50$, and all p values $> .30$) (Table S4 in Supplement 1).

Symptom Measures

The BPRS, SANS, CDS, and CGI-S data are presented in Table 5. The overall ANCOVA revealed nonsignificant treatment effects for BPRS total score [$F(2,54.2) = .17$; $p = .84$]; BPRS positive symptoms items [$F(2,54.4) = 1.01$; $p = .37$]; SANS total score [$F(2,56) = .81$; $p = .45$]; and CDS total score [$F(2,54.3) = .01$; $p = .99$]. There was a significant treatment difference for the CGI-S [$F(2,56.4) = 4.21$; $p = .02$]. The follow-up pair-wise comparisons revealed that participants randomized to MK-0777 3 mg b.i.d. exhibited small but statistically significant worsening on this measure compared with participants assigned to placebo [$t(53.8) = 2.33$; $p = .02$] or to MK-0777 8 mg b.i.d. [$t(53.1) = 2.34$; $p = .02$].

Safety Measures

The study drug was well-tolerated. Only one participant required a reduction in their dose (randomized to MK-0777 8 mg

Table 4. 2-Back Response Times by Treatment and Response Type

Response Type	Week	Mean (SD)		
		Placebo	MK-0777, 3 mg b.i.d.	MK-0777, 8 mg b.i.d.
Target Hit	0	825.8 (228.8)	732.9 (181.9)	822.9 (267.1)
	4	869.6 (286.1)	772.8 (211.0)	768.4 (289.4)
Novel Correct	0	862.2 (337.7)	790.4 (241.0)	773.7 (185.6)
	4	724.9 (279.3)	798.8 (156.7)	766.1 (319.0)
Rejection	0	813.1 (292.8)	767.1 (343.9)	779.6 (265.5)
	4	801.7 (242.7)	861.9 (225.9)	788.3 (318.7)

Values are mean (\pm SD). Analysis of covariance tests for treatment effects: $F(2) = 0.10$, 46.7 , $p = .91$ for overall treatment differences across response type; $F(4,52.2) = 0.29$, $p = 0.88$ for treatment \times response type interaction.

b.i.d.; dose was reduced to 5 mg in the morning and 8 mg in the evening). In pair-wise comparisons between placebo and the two experimental groups, there were no significant treatment differences on the AIMS total score or the SAS total score (Table 6). On the SEC, there were no overall significant treatment differences in the frequency of participants reporting new or worsened side effects (all p values $> .10$) (Table S5 in Supplement 1). There were minor treatment group differences in vital signs (Table S6 in Supplement 1). There were no significant treatment group differences in fasting glucose or cholesterol levels, liver enzymes, or renal measures (all F values < 1.30 , and all p values $> .25$) (Table S7 in Supplement 1).

Discussion

The study results suggest that MK-0777 does not significantly improve cognitive impairments in people with schizophrenia. There were no significant differences between the two MK-0777 treatment arms and placebo on the MCCB composite score. In secondary analyses, participants randomized to placebo compared with those randomized to MK-0777 8 mg b.i.d. exhibited greater improvement on the Brief Visual Memory Test-Revised and the Neuropsychological Assessment Battery mazes tests. However, neither of these two group differences would have been significant after correcting for multiple comparisons. There were no significant group differences on the two ancillary cognitive measures, the N-back and AX-CPT, or on the two functional measures, the UPSA summary score or the SCoRS interviewer global rating score. The

Table 5. Symptom Outcome Measures

Measure	Week	Placebo	MK-0777, 3 mg b.i.d.	MK-0777, 8 mg b.i.d.
BPRS Total Score	0	26.8 (6.4)	28.9 (5.2)	29.8 (6.2)
	4	26.5 (6.5)	28.4 (5.6)	29.7 (6.7)
BPRS Positive Symptom Item Score	0	7.0 (3.5)	7.6 (2.8)	6.8 (2.1)
	4	7.1 (3.6)	6.7 (2.2)	6.7 (2.1)
CDS Total Score	0	1.6 (1.5)	2.1 (2.4)	2.0 (2.1)
	4	1.5 (2.6)	1.7 (2.1)	1.9 (2.3)
SANS Total Score	0	18.6 (11.5)	17.8 (10.5)	20.6 (14.7)
	4	20.2 (10.6)	17.7 (10.7)	21.6 (15.8)
CGI Severity Score	0	3.7 (.6)	3.4 (.7)	3.5 (.9)
	4	3.6 (.7)	3.7 (.8)	3.5 (.9)

Values are mean (\pm SD). The overall ANCOVA test for treatment effects: BPRS total score: $F(2,54.2) = 0.17$; $p = 0.84$; BPRS positive symptoms item score: $F(2,54.4) = 1.01$; $p = 0.37$; SANS total score: $F(2,56) = 0.81$; $p = 0.45$; CDS total score: $F(2,54.3) = 0.01$; $p = 0.99$; Clinical Global Impression severity of illness item (CGI-S): $F(2,56.4) = 4.21$; $p = 0.02$.

Abbreviations as in Tables 1 and 2.

Table 6. AIMS and SAS Total Scores

Measure	Week	Mean		
		Placebo	MK-0777, 3 mg b.i.d.	MK-0777, 8 mg b.i.d.
AIMS Total Score	0	.6 (2.0)	.2 (.3)	.9 (1.5)
	4	.3 (.6)	.2 (.4)	1.0 (2.0)
SAS Total Score	0	1.1 (1.5)	.8 (1.2)	1.4 (1.6)
	4	1.2 (1.3)	.7 (1.0)	1.2 (1.5)

Abnormal Involuntary Movement Scale (AIMS) total score: placebo vs. MK-0777 3 mg b.i.d., $F(1,37) = 0.19, p = .66$; placebo vs. MK-0777 8 mg b.i.d., $F(1,37) = 0.52, p = 0.22$. Simpson-Angus Scale (SAS) total score: placebo vs. MK-0777 3 mg b.i.d., $F(1,34) = 0.65, p = .43$; placebo vs. MK-0777 8 mg b.i.d., $F(1,36) = 0.01, p = 0.91$.

only observed group difference in the UPSA component measures favored the placebo group.

MK-0777 did not exhibit any significant benefits for BPRS total or positive symptom item scores, SANS total score, or CDS total score. In participants randomized to MK-0777 3 mg b.i.d. there was a small but significant worsening on the CGI-S score. Both doses of MK-0777 were well-tolerated with minimal side effects.

The present results stand in contrast to those from the previous MK-0777 study. In particular, Lewis *et al.* (28) found a significant group difference on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) (47) delayed memory index; whereas, in the current study, there were no significant group differences that favored MK-0777 on any of the MCCB test measures. In addition, Lewis *et al.* (28) reported a significant group difference in the combined N-back and Preparing to Overcome Prepotency Task (POP) reaction time measure; there were no other significant group differences on the AX-CPT, N-Back, and POP ancillary measures. In the current study, there were no significant performance or reaction time differences with either the AX-CPT or N-back ancillary measures. There are several possible explanations for these differences between the two studies. The most important of which is the small sample size of the Lewis *et al.* study, which limits the reliability of their estimate of subject test performance and experimental drug effects. Second, although Lewis *et al.* found a significant benefit for MK-0777 for the RBANS delayed memory index, other RBANS measures, including the visuospatial constructional and attention indexes, showed a numerically larger if not statistically significant advantage for placebo, which suggests that the limited benefits observed in the current study might accurately reflect MK-0777 efficacy for neuropsychological test measures. Finally, the group difference in the combined POP/N-back reaction time measure was largely driven by marked slowing of POP RTs in the placebo group. The MK-0777 group showed modest RT decreases on the two measures. In the current study, the placebo participants exhibited decreased RT in two of the three 2-back measures, whereas there tended to be a minimal to small RT increase on these measures in the MK-0777 3 mg b.i.d. group and a minimal to small RT decrease on these measures in the MK-0777 8 mg b.i.d. group.

The MCCB composite score and each of the domain scores exhibited good to excellent test-retest reliability. The placebo group exhibited small but significant practice/learning effects for the MCCB composite score and the verbal learning and reasoning/problem-solving domains.

There are several potential limitations of the current study. The most important is that the sample size is relatively small, so there is a possibility of a type II error (i.e., MK-0777 is truly better than placebo), but there was not sufficient power to detect the difference. However, across all efficacy measures the observed changes

were numerically better in the placebo group, and the only significant differences favored the placebo group. Moreover, the current study used a rigorous study design intended to minimize potential confounding variables in the evaluation of potential cognitive-enhancing drugs (30,34).

If the current study results accurately reflect the cognitive benefits of MK-0777, then what are the implications for future studies of GABA_A α 2 agonists? First, the rationale for the GABA_A α 2 target is compelling, with significant preclinical and clinical evidence to support the hypothesis that a drug that activates this receptor could have cognitive-enhancing effects. However, MK-0777 is a relatively weak GABA_A α 2 partial agonist, with 10%–20% of the potency of a full GABA_A α 2 agonist, and might not represent the most rigorous assessment of the hypothesized mechanism. Moreover, although MK-0777 is relatively selective for the GABA_A α 2 and α 3 receptor units, new or worsened sedation was observed numerically more frequently in the experimental treatment arms than in the placebo arm. In the Lewis *et al.* study, somnolence was reported more frequently in the MK-0777 than placebo group. These sedative effects could have adversely affected cognitive performance—a hypothesis that receives partial support from the observation that participants randomized to MK-0777 were less likely than those randomized to placebo to exhibit practice/learning effects for the MCCB composite score. In combination, these considerations suggest that a more selective agent with greater intrinsic activity at the GABA_A α 2 site might still be worth pursuing for the treatment of cognitive impairments in schizophrenia.

This study was funded by National Institute of Mental Health Contract HHSN278200441003C to the University of California, Los Angeles (SRM, Principal Investigator). Double-blind medications were provided by Merck and Company. We wish to thank the following for their assistance in the conduct of the study: New York State Psychiatric Institute and College of Physicians and Surgeons, Columbia University: Marlene Carlson; Duke University Medical Center: Trina Walker and Leslie Yusko; Massachusetts General Hospital, Harvard Medical School: Shannon Sorenson and Joanne Wojcik; Maryland Psychiatric Research Center: Sharon August and Ilene Verovsky; Washington University in St. Louis School of Medicine: Meghan Flatley and Emily Thomason and UCLA Semel Institute for Neuroscience and Human Behavior: Ayala Ofek and Ewa Witt.

Ms. Ball reported consultant services with ePharmaLearning to provide training for a Pfizer trial. Dr. Barch disclosed the receipt of research funding from the National Institute of Mental Health, the McDonnell Center for Higher Brain Function, National Alliance for Research on Schizophrenia and Depression, Allon, and Novartis. Dr. Buchanan has served as a Data and Safety Monitoring Board member for Cephalon, Otsuka, and Pfizer; a consultant to Abbott, GlaxoSmithKline, Sanofi-Aventis, Schering-Plough; and an Advisory Board member for Abbott, AstraZeneca, Cypress Bioscience, Merck, Pfizer, Roche, Solvay Pharmaceuticals, and Wyeth. He has received grant support from Janssen Pharmaceutica. Dr. Csernansky reported receipt of honoraria for service on Data Monitoring Committees for clinical trials sponsored by Eli Lilly and Sanofi Aventis. Dr. Goff has served as consultant and/or adviser to: Xytis, Forest Laboratories, Pfizer, Indevus Pharmaceuticals, H. Lundbeck, Schering-Plough, Eli Lilly, Takeda, Biovail, Solvay, Hoffman-La Roche, and Daiichi Sumitomo; served on a Data and Safety Monitoring Board for Otsuka and Wyeth; and received research funding from Pfizer, Janssen, Novartis, and GlaxoSmithKline. Dr. Gold disclosed royalties from the brief assessment of cognition in schizophrenia (BACS) and has served as a consultant for Pfizer, Solvay, GlaxoSmithKline, AstraZeneca, and Merck. Dr. Green has been a consultant to Abbot Laboratories, Astellas, Cypress Bioscience, Dainippon

Sumitomo Pharma, GlaxoSmithKline, Lundbeck, Otsuka, Sanofi Aventis, Takeda, and Wyeth and a speaker for Janssen Cilag. Dr. Jarskog has received grant support from Novartis and GlaxoSmithKline. Dr. Javitt serves as Chair, scientific advisory board, and major shareholder of Glytech and Amino Acids Solutions. Over the past 2 years, Dr. Javitt has served as a consultant for pharmaceutical companies, including Sanofi Aventis, Solvay, Organon, Lundbeck, AstraZeneca, NPS Pharmaceuticals, Takeda, and Sepracor. He currently serves on a new treatment development advisory board for Pfizer, serves on the Scientific Advisory Board for Promentis Pharmaceuticals, and has received research support from the pharmaceutical industry, including, in the past year, Pfizer, Roche, and Jazz Pharmaceuticals. Dr. Keefe reports having received investigator-initiated research funding support from the National Institute of Mental Health, Department of Veterans Affairs, Allon, GlaxoSmithKline, Novartis, and the Singapore National Medical Research Council and an unrestricted educational grant from AstraZeneca. He disclosed receiving honoraria and served as a consultant or advisory board member for Abbott, Acadia, AstraZeneca, BiolineRx, BrainCells, Bristol-Myers Squibb, CHDI, Cypress Bioscience, Dainippon Sumitomo Pharma, Eli Lilly, En Vivo, Johnson & Johnson, Lundbeck, Memory Pharmaceuticals, Merck, Neurosearch, NeuroCog Trials, Novartis, Orexigen, Orion, Otsuka, Pfizer, Prophase, Roche, SanofiAventis, Shire, Solvay, Takeda, Wyeth, and Xenoport. Dr. Keefe reports being a shareholder in NeuroCog Trials as well as receiving royalties from the BACS testing battery and the MATRICS Consensus Cognitive Battery (BACS Symbol Coding). Dr. Kern receives financial support from MATRICS Assessment, a nonprofit organization that facilitates the distribution of the MATRICS Consensus Cognitive Battery. He also has received consultation fees from Otsuka. Dr. Kimhy has received an instrument grant from VivoMetrics. Dr. Lieberman received grant/research funding from Allon, GlaxoSmithKline, Merck, Novartis, Pfizer, Sepracor, and Targacept and also served on advisory boards for Bioline, Eli Lilly, GlaxoSmithKline, Intracellular Therapies, Pierre Fabre and Psychogenics; and he holds a patent for Repligen. Dr. Marder reports having received consulting fees from the following companies: Wyeth, Otsuka, Pfizer, Schering Plough, Bristol Meyers Squibb, Roche, Lundbeck, Sanofi Aventis, and Acadia. He received research support from Novartis and GlaxoSmithKline. Dr. McEvoy has received grants from GlaxoSmithKline, Pfizer, and Novartis as well as honoraria from Eli Lilly. Dr. Larry J. Seidman reports no financial disclosures or conflicts of interest for the past 2 years. He has been a speaker for Shire Pharmaceuticals and received an unrestricted education grant from Janssen Pharmaceuticals in the past 5 years. All other authors report no biomedical financial interests or potential conflicts of interest.

Clinicaltrials.gov: MK-0777 for the Treatment of Cognitive Impairments in Patients With Schizophrenia; <http://clinicaltrials.gov/ct2/show/NCT00505076?term=NCT00505076&rank=1;NCT00505076>.

Supplementary material cited in this article is available online.

- Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK (2004): Identification of separable cognitive factors in schizophrenia. *Schizophr Res* 72:29–39.
- Green MF (1996): What are the functional consequences of neurocognitive deficits in schizophrenia? *Am J Psychiatry* 153:321–330.
- Green MF, Kern RS, Heaton RK (2004): Longitudinal studies of cognition and functional outcome in schizophrenia: Implications for MATRICS. *Schizophr Res* 72:41–51.
- Keefe RSE, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, *et al.* (2007): Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. *Arch Gen Psychiatry* 64: 633–647.
- Lewis DA, Hashimoto T, Volk DW (2005): Cortical inhibitory neurons and schizophrenia. *Nat Rev Neurosci* 6:312–324.
- Akbarian S, Kim JJ, Potkin SG, Hagman JO, Tafazzoli A, Bunney WE Jr, Jones EG (1995): Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. *Arch Gen Psychiatry* 52:258–266.
- Volk DW, Austin MC, Pierri JN, Sampson AR, Lewis DA (2000): Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia. *Arch Gen Psychiatry* 57:237–245.
- Guidotti A, Auta J, Davis JM, Gerevini VD, Dwivedi Y, Grayson DR, *et al.* (2000): Decrease in reelin and glutamic acid decarboxylase. 67 (GAD₆₇) expression in schizophrenia and bipolar disorder. *Arch Gen Psychiatry* 57:1061–1069.
- Vawter MP, Crook JM, Hyde TM, Kleinman JE, Weinberger DR, Becker KG, *et al.* (2002): Microarray analysis of gene expression in the prefrontal cortex in schizophrenia: A preliminary study. *Schizophr Res* 58:11–20.
- Hashimoto T, Volk DW, Eggan SM, Mirnics K, Pierri JN, Sun Z, *et al.* (2003): Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. *J Neurosci* 23:6315–6326.
- Volk DW, Austin MC, Pierri JN, Sampson AR, Lewis DA (2001): GABA transporter-1 mRNA in the prefrontal cortex in schizophrenia: Decreased expression in a subset of neurons. *Am J Psychiatry* 158:256–265.
- Woo T-U, Whitehead RE, Melchitzky DS, Lewis DA (1998): A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia. *Proc Natl Acad Sci U S A* 95:5341–5346.
- Pierri JN, Chaudry AS, Woo T-U, Lewis DA (1999): Alterations in chandelier neuron axon terminals in the prefrontal cortex of schizophrenic subjects. *Am J Psychiatry* 156:1709–1719.
- Volk DW, Pierri JN, Fritschy J-M, Auh S, Sampson AR, Lewis DA (2002): Reciprocal alterations in pre- and postsynaptic inhibitory markers at chandelier cell inputs to pyramidal neurons in schizophrenia. *Cereb Cortex* 12:1063–1070.
- Wilson FA, Scalaidhe O, SP, Goldman-Rakic PS (1994): Functional synergism between putative gamma-aminobutyrate-containing neurons and pyramidal neurons in prefrontal cortex. *Proc Natl Acad Sci U S A* 91:4009–4013.
- Rao SG, Williams GV, Goldman-Rakic PS (1999): Isodirectional tuning of adjacent interneurons and pyramidal cells during working memory: Evidence for microcolumnar organization in PFC. *J Neurophysiol* 81: 1903–1916.
- Rao SG, Williams GV, Goldman-Rakic PS (2000): Destruction and creation of spatial tuning by disinhibition: GABA_A blockade of prefrontal cortical neurons engaged by working memory. *J Neurosci* 20:485–494.
- Castner SA, Arriza JL, Roberts JC, Mrzljak L, Christian EP, Williams GV (2010): Reversal of ketamine-induced working memory impairments by the GABA_A $\alpha 2/\alpha 3$ agonist TPA023. *Biol Psychiatry* 67:998–1001.
- Park S, Holzman PS (1992): Schizophrenics show spatial working memory deficits. *Arch Gen Psychiatry* 49:975–982.
- Gold JM, Carpenter C, Randolph C, Goldberg TE, Weinberger DR (1997): Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia. *Arch Gen Psychiatry* 54:159–165.
- Callicott JH, Tallent K, Bertolino A, Ransley N, Santha A, Knable M, *et al.* (1998): fMRI brain mapping in psychiatry. *Neuropsychopharmacology* 18:186–196.
- Carter CS, Perlstein W, Ganguli R, Brar J, Mintun M, Cohen JD (1998): Functional hypofrontality and working memory dysfunction in schizophrenia. *Am J Psychiatry* 155:1285–1287.
- Callicott JH, Mattay VS, Bertolino A, Finn K, Coppola R, Frank JA, *et al.* (1999): Physiological characteristics of capacity constraints in working memory as revealed by functional MRI. *Cereb Cortex* 9:20–26.
- Tek C, Gold J, Blaxton T, Wilk C, Buchanan RW (2002): Visual perceptual and working memory impairments in schizophrenia. *Arch Gen Psychiatry* 59:146–153.
- Atack JR, Wafford KA, Tye SJ, Cook SM, Sohal B, Pike A, *et al.* (2006): TPA023 [7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an agonist selective for $\alpha 2$ - and $\alpha 3$ -containing GABA_A receptors, is a non-sedating anxiolytic in rodents and primates. *J Pharmacol Exp Ther* 316:410–422.
- Atack JR (2008): GABA(A) receptor subtype-selective efficacy: TPA023, an $\alpha 2/\alpha 3$ selective non-sedating anxiolytic and $\alpha 5$, an $\alpha 5$ selective cognition enhancer. *CNS Neurosci Ther* 14:25–35.
- de Haas SL, de Visser SJ, van der Post JP, de Smet M, Schoemaker RC, Rijnbeek B, *et al.* (2007): Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) $\alpha 2,3$ subtype-selective agonist, compared

- to lorazepam and placebo in healthy volunteers. *J Psychopharmacol* 21:374–383.
28. Lewis DA, Cho RY, Carter CS, Eklund K, Forster S, Kelly MA, Montrose D (2008): Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. *Am J Psychiatry* 165:1585–1593.
 29. First MB, Spitzer RL, Gibbon M, Williams J (1997): *Structural Clinical Interview for DSM-IV Axis Disorders (SCID-IV)*. New York: Biometrics Research Department, New York State Psychiatric Institute.
 30. Buchanan RW, Davis M, Goff D, Green MF, Keefe RS, Leon AC, *et al.* (2005): A summary of the FDA-NIMH-MATRICES workshop on clinical trial design for neurocognitive drugs for schizophrenia. *Schizophr Bull* 31:5–19.
 31. Overall JE, Gorham DR (1962): The Brief Psychiatric Rating Scale. *Psychol Rep* 10:799–812.
 32. Simpson GM, Angus JWS (1970): A rating scale for extrapyramidal side effects. *Acta Psychiatr Scand* 212:11–19.
 33. Addington D, Addington J, Schissel B (1990): A depression rating scale for schizophrenics. *Schizophr Res* 3:247–251.
 34. Buchanan RW, Keefe RS, Umbricht D, Green MF, Laughren T, Marder SR (2010): The FDA-NIMH-MATRICES guidelines for clinical trial design of cognitive-enhancing drugs: What do we know 5 years later? *Schizophr Bull* 36:71–93.
 35. Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, *et al.* (2008): The MATRICES Consensus Cognitive Battery, part 1: Test selection, reliability, and validity. *Am J Psychiatry* 165:203–213.
 36. Kern RS, Nuechterlein KH, Green MF, Baade LE, Fenton WS, Gold JM, *et al.* (2008): The MATRICES Consensus Cognitive Battery, part 2: Co-norming and standardization. *Am J Psychiatry* 165:214–220.
 37. Wechsler D (2001): *Wechsler Test of Adult Reading*. San Antonio, Texas: Psychological Corporation.
 38. Cohen JD, Barch DM, Carter C, Servan-Schreiber D (1999): Context-processing deficits in schizophrenia: Converging evidence from three theoretically motivated cognitive tasks. *J Abnorm Psychol* 108:120–133.
 39. Cohen JD, Perlstein WM, Braver TS, Nystrom LE, Noll DC, Jonides J, Smith EE (1997): Temporal dynamics of brain activation during a working memory task. *Nature* 386:604–608.
 40. Patterson TL, Goldman S, McKibbin CL, Hughs T, Jeste DV (2001): UCSD Performance-Based Skills Assessment: Development of a new measure of everyday functioning for severely mentally ill adults. *Schizophr Bull* 27:235–245.
 41. Keefe RSE, Poe M, Walker TM, Kang JW, Harvey PD (2006): The Schizophrenia Cognition Rating Scale: An interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity. *Am J Psychiatry* 163:426–432.
 42. Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, *et al.* (2007): The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): The efficacy of glutamatergic agents for negative symptoms and cognitive impairments. *Am J Psychiatry* 164:1593–1602.
 43. Guy W (1976): *ECDEU Assessment Manual for Psychopharmacology*. US Department of Health and Human Services publication (ADM) 76–338. Rockville, Maryland: US Department of Health and Human Services, 534–535.
 44. Stanislaw H, Todorov N (1999): Calculation of signal detection theory measures. *Behav Res Methods Instrum Comput* 31:137–149.
 45. Conover WJ, Salsburg DS (1988): Locally most powerful tests for detecting treatment effects when only a subset of patients can be expected to “respond” to treatment. *Biometrics* 44:189–196.
 46. McMahon RP, Arndt S, Conley RR (2005): More powerful two-sample tests for differences in repeated measures of adverse effects in psychiatric trials when only some patients may be at risk. *Stat Med* 24:11–21.
 47. Gold JM, Queern C, Iannone VN, Buchanan RW (1999): Repeatable Battery for the assessment of neuropsychological status as a screening test in schizophrenia I: Sensitivity, reliability, and validity. *Am J Psychiatry* 156:1944–1950.